Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing

Highlights • Increasingly once all treatment strategies are exhausted or on development of resistance to targeted therapies it is not uncommon to consider further multiplex targeted sequencing to select targeted therapies as fourth-line treatment in lung adenocarcinoma. • Despite the prospect of imp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-05, Vol.107, p.22-35
Hauptverfasser:	Doble, Brett, John, Thomas, Thomas, David, Fellowes, Andrew, Fox, Stephen, Lorgelly, Paula
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - economics Adenocarcinoma - secondary Adenocarcinoma of Lung Australia Cohort Studies Cost-Benefit Analysis Cost-effectiveness analysis Disease Progression Economic evaluation Genomic testing Genomics Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - economics Lung Neoplasms - secondary Molecular Targeted Therapy - methods Next-generation sequencing Non-small cell lung cancer Oncology Precision Medicine - economics Pulmonary/Respiratory Quality-Adjusted Life Years Sequence Analysis, DNA
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!